Somatropin: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), CONITEC (Brazil) and HAS (France), among others, recommended or restricted somatropin, while AWMSG (Wales) and NYE METODER (Norway) did not recommend it.
PBAC (Australia) has been easier on somatropin than on its own caseload: it refused 0 of 9 decisive submissions here (0%), against a base rate of 24% across everything it has assessed.
The file has been open for more than a decade: 19.8 years separate the first record, 12 Jun 2006 at SMC (Scotland), from the most recent, 15 Mar 2026 at NYE METODER (Norway).
SMC (Scotland) changed its position: restricted on 12 Jun 2006, recommended by 7 Nov 2011.
No assessment is on file from CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for somatropin, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 7 of 51 records date from 2023 or later.
The programme is broad: 10 distinct indication wordings are recorded for somatropin by the agencies that label one in English (AWMSG, PBAC and SMC).
12 of these 51 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess somatropin, on 12 Jun 2006; NYE METODER (Norway) did not open a file until 15 Mar 2026 — an unusually long tail of 19.8 years between the earliest and latest system to look at it.
The record arrives in waves: 15 separate years each carry two or more decisions, spread across 20 years in total.
7 of the 9 agencies here assessed somatropin more than once, HAS (France) most often at 25 entries — repeat review is the norm for this molecule rather than the exception.
9 of the 18 agencies in this archive hold a record for somatropin.
The full ledger for somatropin reads 32 recommended, 10 other, 2 not recommended and 2 restricted, with 5 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2024 | Late onset growth hormone (GH) deficiency | Recommended | source |
| PHARMAC (New Zealand) | 1 Feb 2023 | Short stature due to chronic renal insufficiency, amending GFR to 60ml/min/1.73m2 | PTAC advice: Medium | source |
| AOTMIT (Poland) | 17 Jan 2020 | Genotropin reimbursement recommendation | recommended conditionally | source |
| CONITEC (Brazil) | 3 Nov 2017 | Deficiência do hormônio do crescimento Hipopituitarismo | incorporated into SUS | source |
| HAS (France) | 24 Jul 2013 | Listing (Transparency Committee) | ASMR V | source |
46 further decisions for somatropin, across 9 agencies, are not shown here. They include the most recent record on file, 15 Mar 2026 from NYE METODER (Norway); its outcome is in the subscriber dataset. They link to 19 further source documents.
Related molecules
- pegvisomant — same ATC class H01A — Pituitary and hypothalamic hormones
- somapacitan — same ATC class H01A — Pituitary and hypothalamic hormones
- somatrogon — same ATC class H01A — Pituitary and hypothalamic hormones
- trametinib — also decided by NYE METODER in 2026Q1
- mirvetuximab soravtansine — also decided by NYE METODER in 2026Q1
- osimertinib — also decided by NYE METODER in 2026Q1
Coverage: 51 decisions for somatropin from 9 agencies, 2006 to 2026. Data to 7 Sep 2026. ATC class H01A — Pituitary and hypothalamic hormones. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.